Shorts

From Generic to Personalized Cancer Care in Hours

A New Early-Onset Cancer Program Is Coordinating Fragmented Care

Why Early-Onset Cancer Cases Deserve Attention

Can Engineering Stem Cells to Prevent GVHD Save Health Systems Money?

60% of Early-Onset Cancers May Be Screenable

Does Weight Change How Cancer Cells Behave?

One Child Cured Equals Decades of Life Saved

A Powerful New Way to Measure Cancer Success

A Promising Breakthrough in Platinum-Resistant Ovarian Cancer Survival

IMNN-001: A Broader Approach to Immunotherapy

Cultivating A Culture of Clinical Trials in Pediatrics

Dr Wang on Managing Post-CAR T Infections: Act Fast and Coordinate Care

Why Children Are Not Just ‘Little Adults’ in Cancer Treatment

Dr Wang: Check IgG Early to Prevent Infections After CAR T

Closing the Gap Between Immunotherapy Innovation and Outdated Evaluation Standards

Dr Thaker Highlights Personalized PARP Strategies and the Promise of IMNN-001 in Ovarian Cancer

Giving Patients the Power to Choose

ROSELLA Shows Survival Benefit With Convenient Relacorilant Dosing

BTK Degraders: A New Hope for Resistant CLL

A New Alternative to Phlebotomy

Promising Responses in Ewing Sarcoma Trial

Why Residual Cancer Burden is a Game-Changer for Oncology

Treating High-Risk CLL: Balancing Efficacy and Duration

Why BRAF Testing Is Critical in ATC

Rare but Targetable: Advances in Biliary Tract Cancer

The Sequencing Dilemma in Thyroid Cancer

Future-Proofing Treatment in Younger Patients With CLL

Tackling Resistance in Pancreatic Cancer

Patient Preference: The Heart of CLL Treatment Decisions

Why Every Thyroid Cancer Patient Needs Genomic Analysis